163 related articles for article (PubMed ID: 37623025)
1. Small Bowel Neuroendocrine Tumors-10-Year Experience of the Ottawa Hospital (TOH).
Alfagih A; AlJassim A; Alqahtani N; Vickers M; Goodwin R; Asmis T
Curr Oncol; 2023 Aug; 30(8):7508-7519. PubMed ID: 37623025
[TBL] [Abstract][Full Text] [Related]
2. Small Bowel Adenocarcinoma: 10-Year Experience in a Cancer Center-The Ottawa Hospital (TOH).
Alfagih A; Alrehaili M; Asmis T
Curr Oncol; 2022 Oct; 29(10):7439-7449. PubMed ID: 36290862
[TBL] [Abstract][Full Text] [Related]
3. Surgical Principles in the Management of Small Bowel Neuroendocrine Tumors.
Gangi A; Anaya DA
Curr Treat Options Oncol; 2020 Aug; 21(11):88. PubMed ID: 32862334
[TBL] [Abstract][Full Text] [Related]
4. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW
JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166
[TBL] [Abstract][Full Text] [Related]
5. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
6. The Role of Adding Somatostatin Analogues to Peptide Receptor Radionuclide Therapy as a Combination and Maintenance Therapy.
Yordanova A; Wicharz MM; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Fimmers R; Essler M; Ahmadzadehfar H
Clin Cancer Res; 2018 Oct; 24(19):4672-4679. PubMed ID: 29950352
[No Abstract] [Full Text] [Related]
7. Surgical Management of Small Bowel Neuroendocrine Tumors: Specific Requirements and Their Impact on Staging and Prognosis.
Pasquer A; Walter T; Hervieu V; Forestier J; Scoazec JY; Lombard-Bohas C; Poncet G
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S742-9. PubMed ID: 26014153
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
10. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal Stromal Tumors: 10-Year Experience in Cancer Center-The Ottawa Hospital (TOH).
Alfagih A; AlJassim A; Alshamsan B; Alqahtani N; Asmis T
Curr Oncol; 2022 Sep; 29(10):7148-7157. PubMed ID: 36290839
[TBL] [Abstract][Full Text] [Related]
13. Survival and disease recurrence in patients operated for small intestinal neuroendocrine tumors at a referral hospital.
Folkestad O; Wasmuth HH; Mjønes P; Fougner R; Hauso Ø; Fossmark R
Surg Oncol; 2020 Dec; 35():336-343. PubMed ID: 32979699
[TBL] [Abstract][Full Text] [Related]
14. Role of Primary Tumor Resection for Metastatic Small Bowel Neuroendocrine Tumors.
Hallet J; Law C;
World J Surg; 2021 Jan; 45(1):213-218. PubMed ID: 32797281
[TBL] [Abstract][Full Text] [Related]
15. Relevant prognostic factors in patients with stage IV small intestine neuroendocrine neoplasms.
Maurer E; Heinzel-Gutenbrunner M; Rinke A; Rütz J; Holzer K; Figiel J; Luster M; Bartsch DK
J Neuroendocrinol; 2022 Jan; 34(1):e13076. PubMed ID: 34964186
[TBL] [Abstract][Full Text] [Related]
16. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors.
Pusceddu S; Prinzi N; Tafuto S; Ibrahim T; Filice A; Brizzi MP; Panzuto F; Baldari S; Grana CM; Campana D; Davì MV; Giuffrida D; Zatelli MC; Partelli S; Razzore P; Marconcini R; Massironi S; Gelsomino F; Faggiano A; Giannetta E; Bajetta E; Grimaldi F; Cives M; Cirillo F; Perfetti V; Corti F; Ricci C; Giacomelli L; Porcu L; Di Maio M; Seregni E; Maccauro M; Lastoria S; Bongiovanni A; Versari A; Persano I; Rinzivillo M; Pignata SA; Rocca PA; Lamberti G; Cingarlini S; Puliafito I; Ambrosio MR; Zanata I; Bracigliano A; Severi S; Spada F; Andreasi V; Modica R; Scalorbi F; Milione M; Sabella G; Coppa J; Casadei R; Di Bartolomeo M; Falconi M; de Braud F
JAMA Netw Open; 2022 Feb; 5(2):e220290. PubMed ID: 35201309
[TBL] [Abstract][Full Text] [Related]
17. Incidence and prognosis of patients with small intestinal neuroendocrine tumors in a population based nationwide study.
Snorradottir S; Asgeirsdottir A; Rögnvaldsson S; Jonasson JG; Björnsson ES
Cancer Epidemiol; 2022 Aug; 79():102197. PubMed ID: 35716441
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy following resection of gastroenteropancreatic neuroendocrine tumors provides no recurrence or survival benefit.
Barrett JR; Rendell V; Pokrzywa C; Lopez-Aguiar AG; Cannon J; Poultsides GA; Rocha F; Crown A; Beal E; Michael Pawlik T; Fields R; Panni RZ; Smith P; Idrees K; Cho C; Beems M; Maithel S; Weber S; Erik Abbott D
J Surg Oncol; 2020 Jun; 121(7):1067-1073. PubMed ID: 32153032
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of clinicopathological characteristics, therapeutic strategy and prognosis of 501 patients with gastric neuroendocrine neoplasms attending a single center].
Zhang BL; Lu YX; Liang WQ; Gao YH; Xi HQ; Wang XX; Zhang KC; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):459-466. PubMed ID: 37217354
[No Abstract] [Full Text] [Related]
20. Upfront Small Bowel Resection for Small Bowel Neuroendocrine Tumors With Synchronous Metastases: A Propensity-score Matched Comparative Population-based Analysis.
Bennett S; Coburn N; Law C; Mahar A; Zhao H; Singh S; Zuk V; Myrehaug S; Gupta V; Levy J; Hallet J
Ann Surg; 2022 Nov; 276(5):e450-e458. PubMed ID: 33214481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
